Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 15:10:12 GMT 2023
by
admin
on
Sat Dec 16 15:10:12 GMT 2023
|
Protein Type | RECEPTOR |
Protein Sub Type | |
Sequence Origin | HUMAN |
Sequence Type | COMPLETE |
Record UNII |
TW3XAW0RCY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P55899
Created by
admin on Sat Dec 16 15:10:13 GMT 2023 , Edited by admin on Sat Dec 16 15:10:13 GMT 2023
|
PRIMARY | |||
|
TW3XAW0RCY
Created by
admin on Sat Dec 16 15:10:13 GMT 2023 , Edited by admin on Sat Dec 16 15:10:13 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_96 | 1_159 |
1_198 | 1_252 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_102 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INHIBITOR -> TARGET | |||
|
LIGAND->TARGET | |||
|
LIGAND->TARGET | |||
|
INHIBITOR -> TARGET |
An antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing FcRn from recycling immunoglobulin G (IgG) back into the blood.[2] The medication causes a reduction in overall levels of IgG, including the abnormal acetylcholine receptor (AChR) antibodies that are present in myasthenia gravis.
|
||
|
BINDER->LIGAND | |||
|
LIGAND->TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|